Aradigm ARD-1500 Pipeline ARD-3100 ARD-1100 ARD-1600 ARD iDMS ARD-1500 ARD-1700 Scientific Publications (Treprostinil) Easy to use AERx Essence palm-size device delivering an aqueous formulation of treprostinil could be a significant advancement over the existing treatments for Pulmonary Arterial Hypertension Currently, Aradigm is investigating the application of its AERx...
Remodulin Approvable For Pulmonary Hypertension - - - - BioNews BioWeb Companies Products BioReports - - - - - - Remodulin Approvable For Pulmonary Hypertension United Therapeutics (NASDAQ: UTHR) has received an approvable letter for Remodulin (treprostinil sodium) injection.
Tracleer Efficacious in Children for treatment of pulmonary arterial hypertension (PAH) - - - - BioNews BioWeb Companies Products BioReports - - - - - Tracleer Efficacious in Children for treatment of pulmonary arterial hypertension (PAH) Actelion (Swiss: ATLN) announced yesterday that Tracleer (bosentan) has demonstrated evidence of utility in the treatment of pulmonary arterial hypertension (PAH) in children under the age of 15.
Biotech Tracker news - Sitaxsentan May Stack Up Well Against Other Pulmonary Arterial Hypertension Treatments - - - - BioNews BioWeb Companies Products BioReports - - - - - - Sitaxsentan May Stack Up Well Against Other Pulmonary Arterial Hypertension Treatments-- October 21, 2002.
BiotechTracker - Remodulin for Pulmonary Arterial Hypertension - - - - BioNews BioWeb Companies Products BioReports - - - - - - BiotechTracker - Remodulin for Pulmonary Arterial Hypertension - May 22, 2003 Data presented at the American Thoracic Society meeting demonstrated Remodulin ’s (treprostinil) capacity to aid in the management of patients with liver cirrhosis-related pulmonary arterial hypertension (PAH).
Approved Products_2004.xls LIST OF APPROVED BIOTECHNOLOBY PRODUCTS (Page 1: product 1- 50) Biotechnology companies have already commercialized a great number of drugs.
author: Reijer
Approved Products_2004.xls page 4
author: Reijer
United Therapuetics - ---- About Remodulin ®- Remodulin (treprostinil sodium) Injection is approved as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.Remodulin requires attention to the following: Remodulin should...
United Therapuetics Epoprostenol (Flolan) is the best characterized approved treatment of pulmonary arterial hypertension for patients who are Functional Class III or IV and unresponsive to other therapies.- Clinical trials have demonstrated an improvement in symptoms and exercise tolerance, and a reduction in mortality even if no acute hemodynamic response to drug challenge occurs.- Recent reports have...
Microsoft Word - 8-K 030805.doc On March 8, 2005, United Therapeutics Corporation issued a press release announcing that AFSSAPS, the French drug regulatory agency, has issued an approval letter for Remodulin (treprostinil sodium) Injection for subcutaneous treatment of NYHA Class III Primary Pulmonary Hypertension patients.REMODULIN ® IN...
author: shola
Microsoft Word - 8-K 030805.doc page 6
author: shola
Microsoft Word - 8-K 030805.doc page 3
author: shola
http://www.unither.com/Files/030805.pr.pdf com UNITED THERAPEUTICS ANNOUNCES APPROVAL OF REMODULIN ® IN FRANCE Silver Spring, MD and Research Triangle Park, NC, March 8, 2005: United Therapeutics Corporation (NASDAQ: UTHR) announced today that AFSSAPS, the French drug regulatory agency, has issued an approval letter for Remodulin (treprostinil sodium) Injection for subcutaneous treatment of NYHA Class...
Microsoft Word - 2003 Form 10-Q 9-30-03 FINA.doc On May 21, 2002, the United States Food and Drug Administration (FDA) approved Remodulin (treprostinil sodium) Injection for the treatment of pulmonary arterial hypertension in patients with NYHA class II- IV symptoms to diminish symptoms associated with exercise.Remodulin (...
author: shola
Microsoft Word - 2003 Form 10-Q 9-30-03 FINA.doc page 12
author: shola
Microsoft Word - 2003 Form 10-Q 9-30-03 FINA.doc page 6
author: shola
http://www.unither.com/Files/100702.pdf com CANADIAN HEALTH AUTHORITY APPROVES REMODULIN ® TO TREAT PULMONARY ARTERIAL HYPERTENSION Research Triangle Park, NC and Silver Spring, MD, October 7, 2002: United Therapeutics Corporation (Nasdaq: UTHR) announced today that the Canadian Therapeutics Products Directorate (TPD) has approved Remodulin ® (treprostinil sodium) Injection for the long- term,...
Microsoft Word - 11042002pr.pdf.doc For Immediate Release For Further Information Contact: Andrew Fisher at (202) 483- 7000 Email: AFisher@ unither.REMODULIN TO TREAT PULMONARY ARTERIAL HYPERTENSION RESEARCH TRIANGLE PARK, N.
author: shola
Database R R - investigational drugs, therapies and- vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Database T T - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
Microsoft Word - 11-03-04 Duffy.doc page 4
author: cahl
Microsoft Word - 8-k.112904.doc Food and Drug Administration (FDA) has issued an approval letter for the intravenous use of Remodulin based on data establishing its bioequivalence with the previously approved subcutaneous administration of Remodulin. Remodulin (treprostinil sodium) Injection is now approved as a "continuous subcutaneous infusion or intravenous...
author: shola
Microsoft Word - 8-k.112904.doc page 6
author: shola
duplicates:http://www.unither.com/Files/112404.pr.pdf
http://www.unither.com/Files/112404.pr.pdf Food and Drug Administration (FDA) has issued an approval letter for the intravenous use of Remodulin based on data establishing its bioequivalence with the previously approved subcutaneous administration of Remodulin. Remodulin is immediately...
Microsoft Word - 2004 Form10-Q 9-30-04 FINAL Version.doc On May 21, 2002, the United States Food and Drug Administration (FDA) approved Remodulin (treprostinil sodium) Injection for the treatment of pulmonary arterial hypertension in patients with NYHA class II- IV symptoms to diminish symptoms associated with exercise.
author: nrivera
